Skip to main content
. Author manuscript; available in PMC: 2018 Jul 1.
Published in final edited form as: Neurobiol Dis. 2018 Apr 13;115:182–193. doi: 10.1016/j.nbd.2018.04.010

Fig. 6.

Fig. 6

Multidrug screening. A, LINCs strategy to identify compounds with signatures similar to CBX. B, Fluid-phase endocytosis was analyzed by Alexa 488-dextran uptake (as in Fig. 5C). Data are mean ± s.e.m. from 4 to 8 independent experiments for each small molecule, one-way ANOVA with Holm-Sidak’s multiple comparisons post-hoc for analyzing differences of vehicle treated Cln3R MBECs with respect to all other groups. C, Phosphorylated Cav-1(P-cav1) levels in Cln3R and Cln3−/− MBECs after small molecule treatment. Data represent mean ± s.e.m. from six independent experiments, non-parametric Mann-Whitney test with Bonferroni‘s multiple comparison correction for vehicle treated Cln3−/− MBECs with respect to all other groups. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001. Carbenoxolone (CBX), Enoxolone (Enx), Prednisolone (Prd), α-ketocholesterol (α-KC), BRD-K95814727 (K8), BRD-K30446755 (K4), BRD-K33258928 (K2), BRD-K95985487 (K9).